Table 2.
Treatment-related adverse events (n = 15)
| Adverse event | Patients with events, n (%) | CTC grade |
|---|---|---|
| Injection-site reaction | 15 (100) | 1, 2, 3* |
| Chills | 14 (93) | 1, 2 |
| Fatigue | 13 (87) | 1, 2 |
| Headache | 11 (73) | 1, 2 |
| Myalgia | 10 (67) | 1, 2 |
| Fever | 10 (67) | 1, 2 |
| Arthralgia | 9 (60) | 1, 2 |
| Diarrhea | 4 (27) | 1 |
| Nausea | 3 (20) | 1 |
| Cough | 2 (13) | 1 |
| Lymphadenopathy | 2 (13) | 1 |
| Dizziness | 1 (7) | 1 |
| Night sweats | 1 (7) | 1 |
| Palpitation | 1 (7) | 1 |
| Rhinitis | 1 (7) | 1 |
| Vomiting | 1 (7) | 1 |
CTC indicates Common Terminology Criteria.
*
Single patient (patient 13) with grade 3 AE = grade 3 injection site reaction, terminated from study.